Read the rest here:
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Related Post
- Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development - January 3rd, 2025
- Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics - January 3rd, 2025
- TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses - January 3rd, 2025
- Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office - January 3rd, 2025
- Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Lexicon Appoints Scott Coiante as Chief Financial Officer - January 3rd, 2025
- Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners - January 3rd, 2025
- SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET - January 3rd, 2025
- Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain - January 3rd, 2025
- Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular... - January 3rd, 2025
- Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference - January 3rd, 2025
- Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update - January 3rd, 2025
- Tilray Brands Moves Earnings Date to January 10, 2025, in Observance of the National Day of Mourning - January 3rd, 2025
- ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab - January 3rd, 2025
- Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering - January 1st, 2025
- Galera Therapeutics completes acquisition of Nova Pharmaceuticals - January 1st, 2025
- Burning Rock Announces Results of 2024 Annual General Meeting - January 1st, 2025
- Spectral AI Provides Instructions for Retail Investors on Exercising Publicly-Traded Warrants - January 1st, 2025
- Oncotelic Therapeutics Implements PDAOAI Platform - January 1st, 2025
- Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 - January 1st, 2025
- Firefly Neuroscience Closes on Financing of up to $12.4 Million - January 1st, 2025
- Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA - January 1st, 2025
- SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder - January 1st, 2025
- HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture - January 1st, 2025
- European Commission approves RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with... - December 30th, 2024
- Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA - December 30th, 2024
- Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging - December 30th, 2024
- Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies - December 30th, 2024
- Orion and Marinus terminate agreement for ganaxolone in Europe - December 30th, 2024
- Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson - December 30th, 2024
- Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma - December 30th, 2024
- Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia - December 30th, 2024
- Hit Refresh in the New Year with Tilray's Premium Non-Alcohol Beverage Lineup - December 30th, 2024
- Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth - December 30th, 2024
- New Year, New Chill: Explore the Latest Cannabis Beverages from Solei, Mollo, and XMG - December 30th, 2024
- Avid Bioservices Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by GHO and Ampersand - December 30th, 2024
- Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of... - December 30th, 2024
- Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV - December 30th, 2024
- NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports - December 30th, 2024
- 2024 Rising Stars Shine at iC³ Summit: Celebrating Progress and Setting the Stage for 2025 - December 30th, 2024
- ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 30th, 2024
- Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million - December 30th, 2024
- argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating... - December 28th, 2024
- Park Ha Biological Technology Co., Ltd. Announces Pricing of $4.8 Million Initial Public Offering - December 28th, 2024
- Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split - December 28th, 2024
- Vor Bio Announces $55.6 Million Private Placement - December 28th, 2024
- Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update - December 28th, 2024
- Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. - December 28th, 2024
- Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 27th, 2024
- Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements - December 27th, 2024
- COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization - December 27th, 2024
- Neutrolis Licenses University of Illinois Chicago Patent to Advance Topical Dry Eye Disease Therapy Targeting NETs - December 27th, 2024
- Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia - December 27th, 2024
- Spectral AI Announces Confirmation of Compliance of its Nasdaq Listing Requirements - December 27th, 2024
- Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 27th, 2024
- Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. - December 27th, 2024
- Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute - December 27th, 2024
- SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation - December 27th, 2024
- Optinose Announces 1-for-15 Reverse Stock Split - December 27th, 2024
- Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing... - December 27th, 2024
- Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in... - December 27th, 2024
- Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives - December 27th, 2024
- CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule GLP-1 RA for the Treatment of Obesity and Diabetes - December 25th, 2024
- HCW Biologics Inc. Received NASDAQ Staff Determination Letter - December 25th, 2024
- Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement - December 25th, 2024
- Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity - December 25th, 2024
- Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis... - December 25th, 2024
- GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds - December 25th, 2024
- RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program - December 25th, 2024
- XBiotech Pauses Rheumatology program - December 25th, 2024
- Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment - December 25th, 2024
- Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference - December 25th, 2024
- Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - December 25th, 2024
- Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD - December 25th, 2024
- Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis - December 25th, 2024
Recent Comments